[189 Pages Report] Humanized Mouse and Rat Model Market report categorizes the Global Market by Type (Cell-Based (PBMC, CD34, BLT), Genetic), Application (Neuroscience, Oncology, Hematopoesis, Immunology & Infectious Diseases), End User (Biotechnology Companies & Pharmaceutical, CRO)) & Geography
Browse 94 market data Tables and 42 Figures spread through 189 Pages and in-depth TOC on "Humanized Mouse and Rat Model Market"
Early buyers will receive 10% customization on this report
The oncology segment commanded the largest share of the Humanized Mouse Model Market in 2017
By application, the Humanized Mouse Model Market is categorized into oncology, immunology and infectious diseases, neuroscience, hematopoiesis, toxicology, and other applications. Of all these application segments, oncology accounted for the largest share of the Humanized Mouse Model Market in 2017.
The increasing research activities and growing funding from various governments to carry out research studies on cancer are the major factors driving the growth of this segment.
Cell-based humanized mouse models to grow at the highest CAGR during the forecast period
By type, the Humanized Mouse Model Market is categorized into genetic and cell-based humanized mouse models.
The cell-based humanized mouse models segment is expected to grow at the highest CAGR during the study period (2017-2022). The high growth of this segment can be attributed to the growing applications of cell-based humanized mouse models.
The cell-based humanized mouse models segment is further categorized into CD34, PBMC, and BLT humanized mouse models. In 2017, the CD34 models segment commanded the largest share of the cell-based Humanized Mouse Model Market and is expected to grow at the highest CAGR during the forecast period.
CD34 mouse models are used as in vivo platforms for analyzing the safety and effectiveness of potential new drugs that can modulate the immune system. They are used for long-term studies in the fields of immuno-oncology, infectious disease, and graft versus host disease.
Thus, the growing application areas of CD34 models are expected to trigger the demand for these models in the coming years.
Ask for PDF Brochure @ www.marketsandmarkets.com/pdfdown…ign=PaidPR
Contract Research Organizations (CROs) to dominate the Humanized Mouse Model Market during the forecast period
By end user, the Humanized Mouse Model Market is categorized into pharmaceutical & biotechnology companies, contract research organizations (CRO), and academic & research institutions. The contract research organizations (CROs) segment is projected to grow at the highest CAGR during the forecast period.
Growth in this segment is largely due to the increasing number of pharmaceutical companies outsourcing their preclinical studies to contract research organizations (CROs).
North America dominated the market in 2017
North America dominated the global Humanized Mouse Model Market in 2017. Growth in this regional segment can be attributed to the increasing monoclonal antibody production, preclinical activities by CROs and pharmaceutical R&D, continued and responsible use of animals ensured by animal care organizations, growing biomedical research in the US along with government support for the development of protein drugs, and growing stem cell research in Canada.
The major market players in the Humanized Mouse Model Market include The Jackson Laboratory (US), Taconic Biosciences, Inc. (US), Horizon Discovery Group plc (UK), genOway, S.A.
(France), Charles River Laboratories (US), Harbour Antibodies BV (China), Hera BioLabs (US), Vitalstar Biotechnology Co., Ltd. (China), inGenious Targeting Laboratory (US), AXENIS S.A.S (France), Crown Bioscience, Inc.
(US), Transgenic, Inc. (Japan), and Champions Oncology, Inc. (US). The major players in the humanized rat models market include Horizon Discovery Group plc (UK), Hera BioLabs (US), and Yecuris Corporation (US).
Know more about the Humanized Mouse and Rat Model Market:
Category: Market Research Publishers and RetailersCompany about: MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions. Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth ...